L-asparaginase-induced complete response in a relapsed patient with epstein-barr virus and cytotoxic peripheral T-cell lymphoma not otherwise specified

Internal Medicine

Volumn 49, Issue 22, 2010, Pages 2505-2508

  Takahashi, Tsutomu ^a   Ikejiri, Fumiyoshi ^a   Onishi, Chie ^a   Kawakami, Koshi ^a   Inoue, Masaya ^a   Miyake, Takaaki ^a   Tanaka, Junko ^a   Araki, Asuka ^a   Maruyama, Riruke ^a   Ohshima, Koichi ^b   Suzumiya, Junji ^a  

^a SHIMANE UNIVERSITY HOSPITAL   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Cytotoxic molecule; Epstein barr virus; Hemophagocytic syndrome; L asparaginase; Peripheral T cell lymphoma NOS

Indexed keywords

ASPARAGINASE; C REACTIVE PROTEIN; CARBOPLATIN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN; ETOPOSIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LACTATE DEHYDROGENASE; LATENT MEMBRANE PROTEIN 1; METHYLPREDNISOLONE; PREDNISOLONE; RANIMUSTINE; SOLUBLE INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TRANSCRIPTION FACTOR PAX5; UNINDEXED DRUG; VINCRISTINE; VINDESINE; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; AXILLARY LYMPH NODE; BLOOD CLOTTING DISORDER; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CELL PROLIFERATION; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; DRUG PULSE THERAPY; DRUG RESPONSE; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE REARRANGEMENT; GIANT CELL; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENOMEGALY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INGUINAL LYMPH NODE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG HILUS; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOID CELL; LYMPHOMA CELL; MALE; MEDIASTINUM LYMPH NODE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; PARAAORTIC LYMPH NODE; PERIPHERAL T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA NOT OTHERWISE SPECIFIED; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOUTHERN BLOTTING; T LYMPHOCYTE RECEPTOR GENE; VIRUS LOAD;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION;

EID: 78549239578     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.4083     Document Type: Article

References (15)

1. Pileri SA, Weisenburger DD, Sng I, et al. Peripheral T-cell lymphoma, not otherwise specified. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Eds. IARC, Lyon, France, 2008: 306-308.
2. Vose J, Armitage J, Weisenburger D. International peripheral Tcell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124-4130, 2008.
3. Jaccard A, Petit B, Girault S, et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 20: 110-116, 2009.
4. Yong W, Zheng W, Zhu J, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 88: 647-652, 2009.
5. Obama K, Tara M, Niina K. L-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma. Int J Hematol 69: 260-262, 1999.
6. Tong H, Ren Y, Qian W, et al. Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int J Hematol 90: 303-310, 2009.
7. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2007.
8. Ogura M, Kagami Y, Taji H, et al. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol 77: 503-511, 2003.
9. Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 108: 4163-4169, 2006.
10. Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29: 1284-1293, 2005.
11. Tong H, Ren Y, Liu H, et al. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma 49: 81-87, 2008.
12. Copur MS, Rose M, Gettinger SN. Miscellaneous chemotherapeutic agents. In: Cancer Principles & Practice of Oncology. 8th Ed. Devita VT, Lawrence TS, Rosenberg SA, Eds. Lippincott Williams & Wilkins, Philadelphia, 2008: 490-491.
13. Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 130: 860-868, 2005.
14. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99: 1016-1020, 2008.
15. Yamaguchi M, Kwong Y, Maeda Y, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. J Clin Oncol 28: 584s, 2010 (#8044 abstract).